乳腺癌耐药蛋白(BCRP/ABCG2)的研究进展  

The Research Progress on Breast Cancer Resistance Protein(BCRP/ABCG2)

作　　者：季恒[1] 汪保国[1] 

机构地区：[1]广东省分子流行病学重点实验室广东药学院,广东广州510006

出　　处：《肿瘤药学》2013年第5期326-330,共5页Anti-Tumor Pharmacy

基　　金：广州市国际区域科技合作项目(2011J5200017);广东省高等学校大学生创新实验项目(10573120033)

摘　　要：肿瘤细胞的多药耐药严重影响肿瘤化疗的疗效,研究肿瘤细胞耐药相关蛋白的生理功能及其转运药物的机制,寻找高效的多药耐药蛋白抑制剂是提高肿瘤化疗效果的重要途径。乳腺癌耐药蛋白(BCRP/ABCG2)是一种介导乳腺癌细胞耐药的重要蛋白,在乳腺癌细胞多药耐药的形成中起关键作用。本文将就BCRP/ABCG2蛋白的结构特点、生理功能、在多药耐药中的作用及其抑制剂等方面的研究进展作一综述。Multi-drug resistance （MDR） is the main factor accounting for the failure of cancer chemotherapy. In order to improve the success rate of cancer chemotherapy, it is important to research the function and transport mechanism of multi-drug resistance-associated protein and find high-performance inhibitors of MDR protein. BCRP/ABCG2 is a multi-drug resistance associated protein, which plays a significant role in the process of MDR of breast cancer. In this article we reviewed the research progress on structure characteristics and physiological functions of BCRP/ABCG2 protein, a.s well as its role in MDR and inhibi- tots.

关 键 词：多药耐药 乳腺癌耐药蛋白 抑制剂 基因表达 

分 类 号：R737.9[医药卫生—肿瘤]